A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation

Biosimilars, interchangeability, extrapolation, immunogenicity

Biologic agents have significantly improved the management of serious health conditions over the last two decades, offering better treatment outcomes and quality of life compared to traditional chemotherapy. The cost of biologic drugs is high, leading to increased healthcare expenses. This mirror…

Aug 3^rd • 10 mins read

Opportunities and challenges in biosimilar uptake in oncology

Trastuzumab, Rituximab, biosimiliar agents, emerging agents, cetuximab, bevacizumab, clinical trials, biosimiliars

The U.S. has 10 approved biosimilars, including 3 for oncology, with many more in development, potentially increasing access to expensive biologics. Acceptance by healthcare providers and patients requires extensive education, resolving concerns about immunogenicity, and ensuring interchangeability.…

Jun 26^th • 7 mins read